Skip header and navigation

Narrow By

24 records – page 1 of 2.

Bowel preparation for chronic kidney disease before colonoscopy

https://libcat.nshealth.ca/en/permalink/chpams35387
Nova Scotia Health Authority. Renal Program, Nova Scotia Health Authority. Pharmacy Services. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1475
Available Online
View Pamphlet
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Nova Scotia Health Authority. Pharmacy Services
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Cathartics
Colonoscopy
Renal Insufficiency, Chronic
Subjects (LCSH)
Laxatives
Colonoscopy
Chronic renal failure
Specialty
Medications
Nephrology
Abstract
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
Responsibility
Prepared by: NSHA Renal Program Educators and Pharmacists
Pamphlet Number
1475
Less detail

Cardio-renal clinical challenges

https://libcat.nshealth.ca/en/permalink/provcat33624
David Goldsmith, Adrian Covic, Jonas Spaak, editors. --Cham, Switzerland: Springer , c2015.
Available Online
View e-Book
Location
Online
This book provides a comprehensive overview of the clinical challenges faced during the treatment of patients with cardiorenal syndrome (CRS). The bidirectional link that associates renal and cardiovascular diseases means that patients with CRS have an increased risk of hospital admission and mortality as a result of their coexistence yet, there are no agreed guidelines for their management. Cardio-Renal Clinical Challenges takes clinical presentations and clinical problems as its base, and the…
Available Online
View e-Book
Other Authors
Goldsmith, David
Covic, Adrian
Spaak, Jonas
Responsibility
David Goldsmith, Adrian Covic, Jonas Spaak, editors
Place of Publication
Cham, Switzerland
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (xiii, 234 pages)
ISBN
9783319091624 (electronic bk.)
9783319091617
Subjects (MeSH)
Cardiovascular Diseases - complications
Renal Insufficiency, Chronic - complications
Comorbidity
Subjects (LCSH)
Cardiovascular system - Diseases
Kidneys - Diseases
Heart - Diseases
Abstract
This book provides a comprehensive overview of the clinical challenges faced during the treatment of patients with cardiorenal syndrome (CRS). The bidirectional link that associates renal and cardiovascular diseases means that patients with CRS have an increased risk of hospital admission and mortality as a result of their coexistence yet, there are no agreed guidelines for their management. Cardio-Renal Clinical Challenges takes clinical presentations and clinical problems as its base, and then discusses the evidence for best management of common clinical problems and the reasons for the complex interplay between the cardiac and renal systems. In addition, the link between heart failure and chronic kidney disease (CKD) can impose a considerable epidemiological burden thus this text also aims to address the issue of organizing healthcare to maximize both the opportunities for prevention and best healthcare economic returns.
Contents
Part I. Cardiovascular Disease (CVD) in Chronic Kidney Disease (CKD): Same or Different? -- 1. Epicardial Coronary Heart Disease in CKD: Diagnosis and Management -- 2. Small Vessel Disease in CKD, Diabetes, Obesity and Hypertension -- 3. Sudden Cardiac Death and Arrhythmia in CKD -- 4. Anticoagulation in CKD -- 5. MRA Inhibition in CKD: More Than Salt and Water -- 6. Vascular Effects of Infl ammation and Oxidative Stress in CKD -- 7. Uric Acid, Allopurinol: The Cardio- Renal Silver Bullet? -- 8. FGF23 and Phosphate: Two Cardiovascular Toxins with Distinct Toxicity Profiles? -- 9. Renal Congestion in Heart Failure -- 10. Effect of Vitamin D on Endothelial Function and Blood Pressure -- 11. Vitamin D and Its Effects on the Heart -- Part II. CKD Complicating Cardiovascular Presentations, Treatment and Outcome -- 12. Volume Overload in CKD: Pathophysiology, Assessment Techniques, Consequences and Treatment -- 13. Reversing Arterial Stiffening and Calcifi cation: A Pipe Dream? -- 14. Pulmonary Hypertension in CKD: A New Problem Child -- 15. How to Use Inhibitors of the Renin-Angiotensin- Aldosterone System in Patients with CKD and Heart Failure -- 16. Erectile and Sex Hormone Dysfunction and Cardiovascular Consequences in CKD -- 17. Renal Sympathetic Denervation in the Management of Treatment- Resistant Hypertension -- Part III. New Ways of Working for the Twenty-first Century: Rising to the Challenge of Comorbid Patients -- 18. Future Therapeutic Prospects for Treatment of Cardiorenal Syndromes -- 19. Novel Combination Therapy to Target Heart and Kidney -- 20. Challenging Complex Diseases -- 21. Is “Me, Me, Me” the New “We, We, We”?: Can We Afford (Not) to Take the Plunge into the Personalised, Stratified Medicine Era? -- 22. Psychological Distress in Physical Long-Term Conditions.
Format
e-Book
Location
Online
Less detail

Chronic Kidney Disease and Hypertension

https://libcat.nshealth.ca/en/permalink/provcat38992
Matthew R. Weir, Edgar V. Lerma, editors. --New York, NY: Springer New York : Imprint: Humana Press , c2015.
Available Online
View e-Book
Location
Online
The treatment of hypertension has become the most important intervention in the management of all forms of chronic kidney disease. Chronic Kidney Disease and Hypertension is a current, concise, and practical guide to the identification, treatment and management of hypertension in patients with chronic kidney disease. In depth chapters discuss many relevant clinical questions and the future of treatment through medications and or novel new devices. Written by expert authors, Chronic Kidney Disea…
Available Online
View e-Book
Other Authors
Weir, Matthew R
Lerma, Edgar V
Responsibility
Matthew R. Weir, Edgar V. Lerma, editors
Place of Publication
New York, NY
Publisher
Springer New York : Imprint: Humana Press
Date of Publication
c2015
Physical Description
1 online resource (xiii, 257 p. : 40 illus., 19 illus. in color)
Series Title
Clinical hypertension and vascular diseases
ISBN
9781493919826
9781493919819 (print ed.)
Subjects (MeSH)
Hypertension, Renal - complications
Renal Insufficiency, Chronic - etiology
Abstract
The treatment of hypertension has become the most important intervention in the management of all forms of chronic kidney disease. Chronic Kidney Disease and Hypertension is a current, concise, and practical guide to the identification, treatment and management of hypertension in patients with chronic kidney disease. In depth chapters discuss many relevant clinical questions and the future of treatment through medications and or novel new devices. Written by expert authors, Chronic Kidney Disease and Hypertension provides an up-to-date perspective on management and treatment and how it may re-shape practice approaches tomorrow.
Contents
Changes in Guideline Trends and Applications in Practice: JNC 2013 and the future -- Central BP monitoring, Home BP Monitoring, Ambulatory BP Monitoring in CKD -- Resistant hypertension in patients with chronic kidney disease -- Neurogenic Factors In Hypertension Associated With Chronic Kidney Disease -- Novel Molecules -- Dual Inhibitors: RAAS Blockers/Combination Therapies: What Do All These Trials Mean? -- Renal Sympathetic Denervation -- Novel baroreceptor activation therapy -- Blood Pressure Vaccines -- Masked Hypertension: Does it Lead to CVD or CKD? -- White Coat Hypertension: Do We Really Understand It Now? -- Uric Acid And Hypertension: Is There Really A Link? -- Preeclampsia: Angiogenic factors, blood pressure, and the kidney -- Inflammation and Hypertension -- Genome-Wide Association Studies (Gwas) Of Blood Pressure In Different Populations -- Endocrine Hypertension and Chronic Kidney Disease -- Hypertension in Children with Chronic Kidney Disease -- Obesity/OSA/Metabolic syndrome in pts with CKD and hypertension: the missing link.
Format
e-Book
Location
Online
Less detail

Chronic Kidney Disease : Diagnosis and Treatment

https://libcat.nshealth.ca/en/permalink/provcat45002
Junwei Yang, Weichun He, editors. --Singapore: Springer , c2020.
Available Online
View e-Book
Location
Online
This book provides a comprehensive and systematic review of the latest findings in a wide spectrum of clinically important aspects of chronic kidney disease (CKD), focusing on clinical diagnosis and therapeutics. CKD is a global health problem with a rising morbidity and mortality. The last decade has seen significant improvements in determining the incidence, prevalence, and complications of CKD, mainly thanks to the definitions of CKD developed by the National Kidney Foundation’s Kidney Disea…
Available Online
View e-Book
Other Authors
Yang, Junwei
He, Weichun
Responsibility
Junwei Yang, Weichun He, editors
Place of Publication
Singapore
Publisher
Springer
Date of Publication
c2020
Physical Description
1 online resource (x, 253 p.) : 23 illus., 19 illus. in color
ISBN
9789813291317
9789813291300 (Print ed.)
9789813291324 (Print ed.)
9789813291331 (Print ed.)
Subjects (MeSH)
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - diagnosis
Renal Insufficiency, Chronic - therapy
Specialty
Nephrology
Abstract
This book provides a comprehensive and systematic review of the latest findings in a wide spectrum of clinically important aspects of chronic kidney disease (CKD), focusing on clinical diagnosis and therapeutics. CKD is a global health problem with a rising morbidity and mortality. The last decade has seen significant improvements in determining the incidence, prevalence, and complications of CKD, mainly thanks to the definitions of CKD developed by the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (K/DOQI). However, increased recognition of CKD has led to awareness of the limitations of its clinical diagnosis and treatment, which are essential to patients’ wellbeing. This book is of particular value not only to nephrologists, but also to general practitioners and residents with an interest in CKD. It offers a well-organized exposition of the current knowledge base. Compared with previously published books on kidney disease and CKD, it has a smaller number of more concise chapters. As a result, readers can easily obtain an overview of the most important topics in CKD. We hope that practitioners will gain as much from reading this practical guide to clinical management of CKD as we have from editing it. Junwei Yang is a professor at Nanjing Medical University and a chief physician at the Centre for Kidney Disease, Second Affiliated Hospital, Nanjing, China.
Contents
Part I. Chronic Kidney Disease -- 1. Chronic Kidney Disease: Overview -- 2. Pathophysiology of Chronic Kidney Disease -- 3. Diabetic Kidney Disease -- 4. Hypertensive Kidney Disease -- 5. Pregnancy in Chronic Kidney Disease -- 6. Aging and Chronic Kidney Disease -- 7. Acute Kidney Injury and Chronic Kidney Disease -- 8. Advanced Image Techniques in Chronic Kidney Disease -- Part II. Complications of Chronic Kidney Disease -- 9. Cardiovascular Disease in Chronic Kidney Disease -- 10. Anemia in Chronic Kidney Disease -- 11. Chronic Kidney Disease-Mineral and Bone Disorder, Vitamin D Deficiency, and Secondary Hyperparathyroidism -- 12. Immune Deficiency and Infection in Chronic Kidney Disease -- 13. Nervous System Disorders in Chronic Kidney Disease: Neurocognitive Dysfunction, Depression, and Sleep Disorder -- Part III. Management of Chronic Kidney Disease -- 14. Nutritional Management of Chronic Kidney Disease -- 15. Medication in Chronic Kidney Disease -- 16. Initiation Timing and Modality Option for Renal Replacement Therapy -- 17. Hemodialysis -- 18. Peritoneal Dialysis -- 19. Transplantation.
Format
e-Book
Location
Online
Less detail

Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1465
Available Online
View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Cinacalcet
Renal Insufficiency, Chronic - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Subjects (LCSH)
Chronic renal failure
Hyperparathyroidism
Kidneys--Diseases--Treatment
Abstract
Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
Notes
Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1465
Less detail

Core Concepts in Hypertension in Kidney Disease

https://libcat.nshealth.ca/en/permalink/provcat39727
Ajay K. Singh, Rajiv Agarwal, editors. --New York, NY: Springer , c2016.
Available Online
View e-Book
Location
Online
This guide provides a comprehensive review of the full spectrum of hypertension in chronic kidney disease (CKD). Targeted towards the busy practitioner, the focus of this volume is on various therapies and how to lower blood pressure through lifestyle changes. Specialist patient populations and hypertension and causes of hypertension are also covered in detail. Clinically-focused and authoritative, this resource offers a rationalized approach to diagnosing and treating hypertension in CKD.
Available Online
View e-Book
Other Authors
Singh, Ajay K
Agarwal, Rajiv
Responsibility
Ajay K. Singh, Rajiv Agarwal, editors
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2016
Physical Description
1 online resource (x, 349 p. : 32 illus., 18 illus. in color)
ISBN
9781493964369
9781493964345 (print ed.)
Subjects (MeSH)
Hypertension, Renal
Renal Insufficiency, Chronic
Abstract
This guide provides a comprehensive review of the full spectrum of hypertension in chronic kidney disease (CKD). Targeted towards the busy practitioner, the focus of this volume is on various therapies and how to lower blood pressure through lifestyle changes. Specialist patient populations and hypertension and causes of hypertension are also covered in detail. Clinically-focused and authoritative, this resource offers a rationalized approach to diagnosing and treating hypertension in CKD.
Contents
1. Epidemiology of Hypertension in Chronic Kidney Disease -- 2. Assessment of Hypertension in Chronic Kidney Disease -- 3. Pathophysiology of Hypertension in Chronic Kidney Disease and Dialysis -- 4. Syndromes of Renovascular Hypertension -- 5. Resistant Hypertension in Chronic Kidney Disease -- 6. Hypertension in Pregnancy -- 7. Hypertension in the Dialysis Patient -- 8. Hypertension in the Kidney Transplant Recipient -- 9. Hypertensive Urgencies and Emergencies -- 10. Management of Hypertension in Chronic Kidney Disease -- 11. Genetic Syndromes of Renal Hypertension -- 12. Drug-Induced Hypertension in Chronic Kidney Disease -- 13. Diagnosis and management of hypertension in children with chronic kidney disease -- 14. Devices to Treat Hypertension in Chronic Kidney Disease.
Format
e-Book
Location
Online
Less detail

Dyslipidemias in kidney disease

https://libcat.nshealth.ca/en/permalink/provcat33736
Adrian Covic, Mehmet Kanbay, Edgar V. Lerma, editors. --New York: Springer , c2014.
Available Online
View e-Book
Location
Online
Dyslipidemia in chronic kidney disease is a common clinical problem and growing in prevalence. With the recent publication of clinical practice guidelines on the management of lipid related disorders in patients affected by chronic kidney disease, an up-to-date and comprehensive resource of evidence-based literature is needed. Dyslipidemias in Kidney Disease captures the growing body of information on this subject matter. This book presentsthe latest clinical evidence and management guidance fo…
Available Online
View e-Book
Other Authors
Covic, Adrian
Kanbay, Mehmet
Lerma, Edgar V
Responsibility
Adrian Covic, Mehmet Kanbay, Edgar V. Lerma, editors
Place of Publication
New York
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xxi, 312 pages)
ISBN
9781493905157 (electronic bk.)
9781493905140
Subjects (MeSH)
Dyslipidemias - complications
Renal Insufficiency, Chronic - complications
Subjects (LCSH)
Lipoproteins - Metabolism
Kidneys - Diseases
Abstract
Dyslipidemia in chronic kidney disease is a common clinical problem and growing in prevalence. With the recent publication of clinical practice guidelines on the management of lipid related disorders in patients affected by chronic kidney disease, an up-to-date and comprehensive resource of evidence-based literature is needed. Dyslipidemias in Kidney Disease captures the growing body of information on this subject matter. This book presentsthe latest clinical evidence and management guidance for patients of various demographics and stages of chronic kidney disease. Written for the nephrologist community, as well as cardiologists and general practitioners, this guide will provide practical knowledge and fill a much needed void in the literature.
Contents
Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidney Disease -- Lipid Nephrotoxicity: New Concept for an Old Disease -- Hyperlipidemia as a Risk Factor for Progression of CKD in Nondiabetics -- How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly -- CVD in CKD: Focus on the Dyslipidemia Problem -- The CKD Patient with Dyslipidemia -- Review of Clinical Trials Pertaining to Dyslipidemias in CKD -- Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease -- Non-statin Therapies for CKD with Dyslipidemia -- Dyslipidemia in Dialysis -- Dyslipidemia in the Kidney Transplant Patient -- Dyslipidemia in Nephrotic Syndrome -- Dyslipidemias in the Pediatric Chronic Kidney Disease Patient -- Dyslipidemias in the Geriatric Chronic Kidney Disease Patients -- Apheresis Methods in Hyperlipidemias -- Review of Current Guidelines: National Cholesterol Education Program and Kidney Disease Outcomes Quality Initiative as They Apply to CKD with Dyslipidemias.
Format
e-Book
Location
Online
Less detail

Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke

https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
2217
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Neoplasms
Stroke
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Cancer
Cerebrovascular disease
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
Responsibility
Prepared by: Renal Program
Pamphlet Number
2217
Less detail

Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1493
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1493
Less detail

A healthy food guide for people with chronic kidney disease

https://libcat.nshealth.ca/en/permalink/provcat20817
American Dietetic Association. Renal Practice Group. (2nd ed.) --Chicago, IL: American Dietetic Association , 2002.
Call Number
WJ 300 H434 2002
Location
Dickson Building
Call Number
WJ 300 H434 2002
Corporate Author
American Dietetic Association. Renal Practice Group
Other Authors
Harvey, Kathy Schiro
Edition
2nd ed.
Alternate Title
National renal diet
Place of Publication
Chicago, IL
Publisher
American Dietetic Association
Date of Publication
2002
Physical Description
32 p.
ISBN
0880914017
Subjects (MeSH)
Kidney Failure, Chronic - diet therapy
Renal Insufficiency, Chronic - diet therapy
Notes
"National Renal diet"--t.p.
Format
Book
Publication Type
Popular Works
Location
Dickson Building
Loan Period
3 weeks
Less detail

Kidney Disease in the Cardiac Catheterization Laboratory : A Practical Approach

https://libcat.nshealth.ca/en/permalink/provcat45302
Janani Rangaswami, Edgar V. Lerma, Peter A. McCullough, editors. --Cham: Springer , c2020.
Available Online
View e-Book
Location
Online
This book is the first title that focuses exclusively on kidney disease and its impact in the cardiac catheterization laboratory. The increasing prevalence of vascular risk factors such as diabetes, obesity and hypertension coupled with increased longevity has resulted in a worldwide epidemic of cardiovascular and chronic kidney disease (CKD). Never has the impact of one organ system on the other been so profound, as in the current context of cardio-renal interactions. The cross talk between th…
Available Online
View e-Book
Other Authors
Rangaswami, Janani
Lerma, Edgar V.
McCullough, Peter A.
Responsibility
Janani Rangaswami, Edgar V. Lerma, Peter A. McCullough, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2020
Physical Description
1 online resource (xx, 473 p.) : 59 illus., 40 illus. in color
ISBN
9783030454142
9783030454135 (Print ed.)
9783030454159 (Print ed.)
9783030454166 (Print ed.)
Subjects (MeSH)
Cardiac Catheterization
Cardio-Renal Syndrome - prevention & control
Contrast Media - adverse effects
Endovascular Procedures
Renal Insufficiency, Chronic - complications
Specialty
Cardiology
Nephrology
Abstract
This book is the first title that focuses exclusively on kidney disease and its impact in the cardiac catheterization laboratory. The increasing prevalence of vascular risk factors such as diabetes, obesity and hypertension coupled with increased longevity has resulted in a worldwide epidemic of cardiovascular and chronic kidney disease (CKD). Never has the impact of one organ system on the other been so profound, as in the current context of cardio-renal interactions. The cross talk between the heart and kidneys is highly relevant in the field of interventional cardiology, given the increasing number of trans-catheter procedures being performed in patients with underlying kidney disease. These procedures also have a significant impact on kidney function and require thoughtful interdisciplinary planning by a cardiorenal team, to achieve optimal outcomes This book assembles the collective expertise of several international leaders in the field of interventional cardiology and nephrology to summarize this complex interface. The book is divided into seven sections to comprehensively cover the topic, including sections on best practices with reduction of contrast associated acute kidney injury, cutting edge techniques to minimize kidney risk with complex interventions, impact of transcatheter valvular procedures on kidney function and the utility of cardio-nephrology teams. Less recognized complications with high morbidity such as athero-embolic renal disease are featured prominently, to increase awareness in the interventional cardiology and nephrology communities. This book is a valuable resource for interventional and structural cardiologists, general cardiologists and nephrologists dealing with the significant overlap areas between these two specialties. It is also relevant to medical students, trainee physicians in nephrology and cardiology, advanced care practitioners and nursing personnel in both specialties . Given the major impact of kidney function on outcomes in patients undergoing cardiac procedures, this textbook serves as a focal point to integrate relevant clinical data from both specialties and help interventional cardiologists achieve optimal outcomes, especially in patients with (or at risk for) kidney disease.
Contents
Part I. Atherosclerotic Cardiovascular Disease Burden in Chronic Kidney Disease -- 1. The Burden of Coronary Artery Disease in Chronic Kidney Disease -- 2. Non-invasive Testing in the Diagnosis of Ischemic Heart Disease in CKD: Scope, Pitfalls, and Future Directions -- 3. Peripheral Arterial Disease in Chronic Kidney Disease: Disease Burden, Outcomes, and Interventional Strategies -- 4. Cardiovascular Impact of Atherosclerotic Renovascular Disease -- Part II. Therapeutic Considerations with Revascularization in Chronic Kidney Disease -- 5. Therapeutic Considerations with Revascularization in Chronic Kidney Disease: Radial Versus Femoral Arterial Access -- 6. Antiplatelet Agent Choice and Platelet Function Testing in CKD -- 7. Choice of Stents and Clinical Outcomes in Patients with Chronic Kidney Disease -- 8. Revascularization Strategies in Chronic Kidney Disease: Percutaneous Coronary Interventions Versus Coronary Artery Bypass Graft -- 9. Approach to Revascularization in the Potential Kidney Transplant Recipient -- 10. Nephrology Consultative Approach and Risk Stratification Prior to Revascularization in Chronic Kidney Disease -- Part III. Acute Kidney Injury in the Catheterization Laboratory: Part I -- 11. Contrast-Induced Acute Kidney Injury: Epidemiology, Risk Stratification, and Prognosis -- 12. Pathophysiology of Contrast Induced Acute Kidney Injury -- 13. Prevention of Contrast-Induced AKI: Summary of Volume Optimization Strategies -- 14. Operator and Intraprocedural Strategies to Reduce Contrast-Induced Acute Kidney Injury -- Part IV. Acute Kidney Injury in the Catheterization Laboratory: Part II -- 15. Effect of Acute Mechanical Circulatory Support on Kidney Function -- 16. Renal Athero-embolic Disease: An Underdiagnosed Entity in Cardiac Catheterization -- 17. Acute Kidney Injury After Transcatheter Aortic Valve Replacement -- 18. Impact of Kidney Disease on Catheter-Based Mitral Valve Interventions -- 19. Contrast-Induced Nephropathy After Peripheral Vascular Intervention -- Part V. Catheter Based Reno-Vascular Interventions -- 20. Renal Artery Stenosis: State of the Art in the Diagnosis and Management -- 21. Renal Denervation: Physiology, Scope, and Current Evidence -- 22. Forced Matched Diuresis: Role in Renal Protection in the Cardiac Catheterization Laboratory -- Part VI. Role of Hemodynamic Evaluation in the Catheterization Laboratory -- 23. Traditional and Novel Invasive Hemodynamic Indices in the Evaluation of Congestive Heart Failure in Cardiorenal Syndrome -- 24. Pulmonary Hypertension in Chronic Kidney Disease -- Part VII. Utility of the Cardio-Nephrology Collaborative in the Cardiac Catheterization Laboratory -- 25. The Economic Impact of Kidney Disease in the Cardiac Catheterization Laboratory -- 26. Biomarkers of Acute Kidney Injury and Scope of Utilization in the Cardiac Catheterization Laboratory -- 27. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine.
Format
e-Book
Location
Online
Less detail

The Kidney in Heart Failure

https://libcat.nshealth.ca/en/permalink/provcat30983
George L. Bakris, editor. --New York, NY: Springer , c2012.
Available Online
View e-Book
Location
Online
Chronic Kidney Disease (CKD) is a recognized risk factor for cardiovascular events and death. The coexistence of CKD and heart failure is increasing in prevalence worldwide and requires a unique and subtle approach to patient management. The Kidney in Heart Failure focuses on the changes that occur in kidney physiology as a function of a failing heart. This comprehensive resource covers epidemiology, pathophysiology, management of kidney disorders and advances in nephropathy management. In add…
Available Online
View e-Book
Other Authors
Bakris, George L, 1952-
Responsibility
George L. Bakris, editor
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (xiv, 248 p. : 44 ill., 14 ill. in color)
ISBN
9781461436942
Subjects (MeSH)
Heart Failure - etiology
Heart Failure - physiopathology
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - physiopathology
Subjects (LCSH)
Cardiology
Nephrology
Abstract
Chronic Kidney Disease (CKD) is a recognized risk factor for cardiovascular events and death. The coexistence of CKD and heart failure is increasing in prevalence worldwide and requires a unique and subtle approach to patient management. The Kidney in Heart Failure focuses on the changes that occur in kidney physiology as a function of a failing heart. This comprehensive resource covers epidemiology, pathophysiology, management of kidney disorders and advances in nephropathy management. In addition, the latest therapies, common heart failure dilemmas and kidney disease markers are included. Each chapter is co-authored by a Nephrologist and Cardiologist, offering a unified perspective to these chronic conditions. This indispensible volume provides the reader with the depth-of-knowledge needed for assessing and treating the cardio renal patient.
Contents
Part I. Epidemiology -- Chronic Kidney Disease and Heart Failure: Epidemiology and Outcomes -- Anemia and Cardiovascular Risk in the Kidney Disease Patients: What Is the Best Way to Achieve and What Is the Desired Hemoglobin? -- Part II. Pathophysiology -- Renal Hemodynamic Changes in Heart Failure -- Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade -- Extracellular Fluid Volume in the Hypoalbuminemic Diabetic Patient -- B-Type Natriuretic Peptide: Beyond Diagnostic Applications -- Part III. Management of Kidney-Associated Clinical Problems -- Hyperkalemia Risk and Treatment of Heart Failure -- Management of Heart Failure with Renal Artery Ischaemia -- Renal Consequences of Prostaglandin Inhibition in Heart Failure -- Edema Mechanisms in the Heart Failure Patient and Treatment Options -- Ultrafiltration and Heart Failure -- Part IV. Advances in Nephropathy Management: Influences on CVD Risk -- Combination Therapy in Hypertension Treatment -- Medication Adherence in Heart Failure -- New Markers of Vascular Risk -- Dietary Paradoxes to Optimize Cardiovascular Risk Management in Chronic Kidney Disease.
Format
e-Book
Location
Online
Less detail

Lanthanum (Fosrenol) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1466
Available Online
View Pamphlet
Lanthanum (LAN-tha-num) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. People with kidney disease are less able to remove phosphorus from the body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. This makes them weaker. Hemodialysis can remove some of the extra phosphorus, but medicin…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Lanthanum
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Lanthanum (LAN-tha-num) is a medicine used to treat high levels of phosphorus (a mineral that builds strong bones and teeth) in the body. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. People with kidney disease are less able to remove phosphorus from the body. When phosphorus levels in the blood get too high, it pushes calcium out from your bones. This makes them weaker. Hemodialysis can remove some of the extra phosphorus, but medicines such as lanthanam are often needed to help remove more. How to take the medicine and what side effects to watch for are reviewed. Fosrenol® is a brand name for lanthanum.
Notes
Previous title: Fosrenol (Lanthanum) and hemodialysis
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1466
Less detail

Management of chronic kidney disease : a clinician's guide

https://libcat.nshealth.ca/en/permalink/provcat33898
Mustafa Arici, editor. --Heidelberg: Springer , c2014.
Available Online
View e-Book
Location
Online
This book presents a comprehensive and instructive management plan for physicians who care for CKD patients. Basic aspects of CKD, clinical assessment, evaluation and management of risk factors, cardiovascular disease in the context of CKD, assessment and management of CKD complications, special circumstances in CKD patients, and the path to renal replacement therapy are all thoroughly covered. Diagnostic and therapeutic approaches are presented according to the latest staging system for CKD, w…
Available Online
View e-Book
Other Authors
Arici, Mustafa
Responsibility
Mustafa Arici, editor
Alternate Title
Managing chronic kidney disease
Place of Publication
Heidelberg
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xvii, 513 pages)
ISBN
9783642546372 (electronic bk.)
9783642546365
Subjects (MeSH)
Renal Insufficiency, Chronic - therapy
Subjects (LCSH)
Chronic renal failure - Treatment
Abstract
This book presents a comprehensive and instructive management plan for physicians who care for CKD patients. Basic aspects of CKD, clinical assessment, evaluation and management of risk factors, cardiovascular disease in the context of CKD, assessment and management of CKD complications, special circumstances in CKD patients, and the path to renal replacement therapy are all thoroughly covered. Diagnostic and therapeutic approaches are presented according to the latest staging system for CKD, with patient care being discussed separately for each disease stage. The proposed management plan is both 'best available evidence based' and 'practice based'. The book also recognizes the needs of busy clinicians by including helpful boxes summarizing the evidence on diagnostic and therapeutic issues and practice pearls based on guidelines.
Contents
CKD: Basics and Clinical Assessment -- CKD Risk Factors: Assessment and Management -- CKD and Cardiovascular Diseases -- CKD Complications: Assessment and Management -- CKD: Special Conditions -- CKD: Final Path to Renal Replacement Therapy.
Format
e-Book
Location
Online
Less detail

Managing the Kidney when the Heart is Failing

https://libcat.nshealth.ca/en/permalink/provcat30982
George L. Bakris, editor. --New York, NY: Springer , c2012.
Available Online
View e-Book
Location
Online
The presence of Chronic Kidney Disease (CKD) increases the risk of death from cardiovascular causes and makes the management of heart failure difficult. The coexistence of CKD and heart failure is increasing in prevalence worldwide and requires a unique and subtle approach to patient management. Managing the Kidney in Heart Failure focuses on the therapeutic management of cardio renal patients. Common heart and kidney failure conditions are presented along with treatment scenarios aimed to red…
Available Online
View e-Book
Other Authors
Bakris, George L, 1952-
Responsibility
George L. Bakris, editor
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (xi, 118 p. : 16 ill., 13 ill. in color)
ISBN
9781461436911
Subjects (MeSH)
Heart Failure - complications
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - therapy
Subjects (LCSH)
Cardiology
Nephrology
Notes
"This book is a compilation of selected chapters originally published in Bakris, The Kidney in Heart Failure"--t.p. verso.
Abstract
The presence of Chronic Kidney Disease (CKD) increases the risk of death from cardiovascular causes and makes the management of heart failure difficult. The coexistence of CKD and heart failure is increasing in prevalence worldwide and requires a unique and subtle approach to patient management. Managing the Kidney in Heart Failure focuses on the therapeutic management of cardio renal patients. Common heart and kidney failure conditions are presented along with treatment scenarios aimed to reduce cardiovascular mortality and preserve kidney function. Co-authored by a Nephrologist and Cardiologist, each chapter of this concise and practical handbook offers a unified perspective to these chronic conditions.
Contents
Chronic Kidney Disease and Heart Failure: Epidemiology and Outcomes -- Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin–Angiotensin System Blockade -- Hyperkalemia Risk and Treatment of Heart Failure -- Management of Heart Failure with Renal Artery Ischaemia -- Combination Therapy in Hypertension Treatment -- Edema Mechanisms in the Heart Failure Patient and Treatment Options -- Ultrafiltration and Heart Failure.
Format
e-Book
Location
Online
Less detail

One-Alpha® (alfacalcidol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1470
Available Online
View Pamphlet
One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. One-Alpha® is a brand name for alfacalcidol.
Responsibility
Prepared by: Renal Pharmacy Team, NSHA Renal Program
Pamphlet Number
1470
Less detail

Oral irons and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35375
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1469
Available Online
View Pamphlet
Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Alternate Title
Oral irons and CKD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Renal Insufficiency, Chronic - drug therapy
Anemia, Iron-Deficiency - drug therapy
Subjects (LCSH)
Chronic renal failure--Complications
Iron deficiency anemia
Renal pharmacology
Abstract
Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1469
Less detail

Over-the-counter medications & chronic kidney disease

https://libcat.nshealth.ca/en/permalink/chpams35643
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1636
Available Online
View Pamphlet
If you have chronic kidney disease, you need to be aware of certain over-the-counter medications that are your best choices and those that could cause unpleasant side effects. This pamphlet lists common ailments (e.g., cough and cold, fever or pain, allergies, upset stomach or heartburn, nausea or vomiting, diarrhea, constipation) and over-the-counter medications that are your best choices, their costs, and medications to stay away from. It also lists your best choices for multivitamins, creams…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([6] p.) : digital, PDF file
Subjects (MeSH)
Nonprescription Drugs
Renal Insufficiency, Chronic - drug therapy
Subjects (LCSH)
Drugs, Nonprescription
Chronic renal failure
Specialty
Medications
Abstract
If you have chronic kidney disease, you need to be aware of certain over-the-counter medications that are your best choices and those that could cause unpleasant side effects. This pamphlet lists common ailments (e.g., cough and cold, fever or pain, allergies, upset stomach or heartburn, nausea or vomiting, diarrhea, constipation) and over-the-counter medications that are your best choices, their costs, and medications to stay away from. It also lists your best choices for multivitamins, creams and ointments, and gives information on why herbal products are not recommended.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1636
Less detail

Parathyroid Glands in Chronic Kidney Disease

https://libcat.nshealth.ca/en/permalink/provcat45256
Adrian Covic, David Goldsmith, Pablo A. Ureña Torres, editors. --Cham: Springer , c2020.
Available Online
View e-Book
Location
Online
This concise book provides practical strategies to help nephrologists and endocrinologists correctly diagnose and treat the various forms of parathyroid disease they may encounter in the management of chronic kidney disease. Each chapter deals with various topics related to parathyroid gland anatomy and physiology, as well as diagnostic tests and their particularities in regard to chronic disease. The book highlights the range of therapies used for the treatment of secondary hyperparathyroidism…
Available Online
View e-Book
Other Authors
Covic, Adrian
Goldsmith, David
Ureña Torres, Pablo A.
Responsibility
Adrian Covic, David Goldsmith, Pablo A. Ureña Torres, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2020
Physical Description
1 online resource (vi, 196 p.) : 21 illus., 18 illus. in color
ISBN
9783030437695
9783030437688 (Print ed.)
9783030437701 (Print ed.)
9783030437718 (Print ed.)
Subjects (MeSH)
Parathyroid Glands - physiopathology
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - physiopathology
Specialty
Endocrinology
Nephrology
Abstract
This concise book provides practical strategies to help nephrologists and endocrinologists correctly diagnose and treat the various forms of parathyroid disease they may encounter in the management of chronic kidney disease. Each chapter deals with various topics related to parathyroid gland anatomy and physiology, as well as diagnostic tests and their particularities in regard to chronic disease. The book highlights the range of therapies used for the treatment of secondary hyperparathyroidism, and critically analyses the latest research in the field. Providing an up-to-date review of the current literature, including innovations in both medical and surgical treatment and current indications for parathyroidectomy, this practice-oriented book is an excellent resource for nephrologists, endocrinologists, endocrine surgeons and family medicine physicians.
Contents
Parathyroid Glands in CKD: Anatomy, Histology, Physiology and Molecular Biology in CKD -- PTH Regulation by the Klotho/FGF23 Axis in CKD -- Parathyroid Imaging in Patients with Renal Hyperparathyroidism -- PTH Receptors and Skeletal Resistance to PTH Action -- PTH Regulation by Phosphate and miRNAs -- PTH Measurement in CKD -- Relation Between PTH and Biochemical Markers of MBD -- Effect of PTH on the Hematologic System -- Parathyroid Hormone as a Uremic Toxin -- Control of Secondary Hyperparathyroidism (SPHT) by Older and Newer Vitamin D Compounds -- The Role of the Old and the New Calcimimetic Agents in Chronic Kidney Disease-Mineral and Bone Disorder -- Parathyroidectomy in Chronic Kidney Disease -- Relation Between PTH and the Risk of Mortality in CKD.
Format
e-Book
Location
Online
Less detail

Rocaltrol® (calcitriol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1468
Available Online
View Pamphlet
Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Calcitriol
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. Rocaltrol® is a brand name for calcitriol.
Responsibility
Prepared by: Renal Pharmacy Team, NSHA Renal Program
Pamphlet Number
1468
Less detail

24 records – page 1 of 2.